Pilot study of the antiplatelet effect of increased clopidogrel maintenance dosing and its relationship to CYP2C19 genotype in patients with high on-treatment reactivity

JACC: Cardiovascular Interventions

Volumn 3, Issue 10, 2010, Pages 1001-1007

  Barker, Colin M ^a   Murray, Sarah S ^c   Teirstein, Paul S ^b,c   Kandzari, David E ^b   Topol, Eric J ^b,c   Price, Matthew J ^b,c  

^a UNIVERSITY OF TEXAS   (United States)

^b SCRIPPS CLINIC   (United States)

^c SCRIPPS TRANSLATIONAL SCIENCE INSTITUTE   (United States)

Author keywords

clopidogrel; CYP2C19; platelet; thienopyridine

Indexed keywords

ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; CYTOCHROME P450 2C19;

ADULT; AGED; ARTICLE; BODY MASS; CLINICAL ARTICLE; DRUG EFFECT; DRUG MEGADOSE; FEMALE; GENE FREQUENCY; GENETIC VARIABILITY; GENOTYPE; HOMOZYGOSITY; HUMAN; LOADING DRUG DOSE; MALE; PATIENT COMPLIANCE; PERCUTANEOUS CORONARY INTERVENTION; PILOT STUDY; PRIORITY JOURNAL; THROMBOCYTE ACTIVATION; TREATMENT DURATION;

AGED; ARYL HYDROCARBON HYDROXYLASES; BODY MASS INDEX; CALIFORNIA; CHI-SQUARE DISTRIBUTION; CORONARY ARTERY DISEASE; FEMALE; GENOTYPE; HUMANS; LOGISTIC MODELS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; PHENOTYPE; PILOT PROJECTS; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PLATELET FUNCTION TESTS; POLYMORPHISM, GENETIC; PREDICTIVE VALUE OF TESTS; RECEPTORS, PURINERGIC P2Y12; RISK ASSESSMENT; RISK FACTORS; TICLOPIDINE;

EID: 77958571929     PISSN: 19368798     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jcin.2010.07.012     Document Type: Article

References (38)

1. C.M. Barker, and M.J. Price Antiplatelet therapy in acute coronary syndromes Curr Cardiol Rep 10 2008 327 333
2. M.J. Price, J.L. Coleman, S.R. Steinhubl, G.B. Wong, C.P. Cannon, and P.S. Teirstein Onset and offset of platelet inhibition after high-dose clopidogrel loading and standard daily therapy measured by a point-of-care assay in healthy volunteers Am J Cardiol 98 2006 681 684
3. M.J. Price, S. Endemann, and R.R. Gollapudi Prognostic significance of post-clopidogrel platelet reactivity assessed by a point-of-care assay on thrombotic events after drug-eluting stent implantation Eur Heart J 29 2008 992 1000
4. G. Patti, A. Nusca, F. Mangiacapra, L. Gatto, A. D'Ambrosio, and G. Di Sciascio Point-of-care measurement of clopidogrel responsiveness predicts clinical outcome in patients undergoing percutaneous coronary intervention results of the ARMYDA-PRO (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty-Platelet Reactivity Predicts Outcome) study J Am Coll Cardiol 52 2008 1128 1133
5. R. Marcucci, A.M. Gori, and R. Paniccia Cardiovascular death and nonfatal myocardial infarction in acute coronary syndrome patients receiving coronary stenting are predicted by residual platelet reactivity to ADP detected by a point-of-care assay: a 12-month follow-up Circulation 119 2009 237 242
6. N.J. Breet, J.W. van Werkum, and H.J. Bouman Comparison of platelet function tests in predicting clinical outcome in patients undergoing coronary stent implantation JAMA 303 2010 754 762
7. P.A. Gurbel, K.P. Bliden, and K. Guyer Platelet reactivity in patients and recurrent events post-stenting: results of the PREPARE POST-STENTING Study J Am Coll Cardiol 46 2005 1820 1826
8. D. Sibbing, S. Braun, and T. Morath Platelet reactivity after clopidogrel treatment assessed with point-of-care analysis and early drug-eluting stent thrombosis J Am Coll Cardiol 53 2009 849 856
9. T. Cuisset, C. Frere, and J. Quilici High post-treatment platelet reactivity is associated with a high incidence of myonecrosis after stenting for non-ST elevation acute coronary syndromes Thromb Haemost 97 2007 282 287
10. C. Frere, T. Cuisset, and J. Quilici ADP-induced platelet aggregation and platelet reactivity index VASP are good predictive markers for clinical outcomes in non-ST elevation acute coronary syndrome Thromb Haemost 98 2007 838 843
11. T. Geisler, H. Langer, and M. Wydymus Low response to clopidogrel is associated with cardiovascular outcome after coronary stent implantation Eur Heart J 27 2006 2420 2425
12. J.M. Pereillo, M. Maftouh, and A. Andrieu Structure and stereochemistry of the active metabolite of clopidogrel Drug Metab Dispos 30 2002 1288 1295
13. F. Marin, R. Gonzalez-Conejero, P. Capranzano, T.A. Bass, V. Roldan, and D.J. Angiolillo Pharmacogenetics in cardiovascular antithrombotic therapy J Am Coll Cardiol 54 2009 1041 1057
14. J.-S. Hulot, A. Bura, and E. Villard Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects Blood 108 2006 2244 2247
15. D. Trenk, W. Hochholzer, and M.F. Fromm Cytochrome P450 2C19 681G>A polymorphism and high on-clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective percutaneous coronary intervention with drug-eluting or bare-metal stents J Am Coll Cardiol 51 2008 1925 1934
16. J.T. Brandt, S.L. Close, and S.J. Iturria Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel J Thromb Haemost 5 2007 2428 2436
17. C. Varenhorst, S. James, and D. Erlinge Genetic variation of CYP2C19 affects both pharmacokinetic and pharmacodynamic responses to clopidogrel but not prasugrel in aspirin-treated patients with coronary artery disease Eur Heart J 30 2009 1744 1752
18. A.R. Shuldiner, J.R. O'Connell, and K.P. Bliden Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy JAMA 302 2009 849 857
19. M.J. Price Bedside evaluation of thienopyridine antiplatelet therapy Circulation 119 2009 2625 2632
20. M.J. Price, K.R. Nayak, C.M. Barker, D.E. Kandzari, and P.S. Teirstein Predictors of heightened platelet reactivity despite dual-antiplatelet therapy in patients undergoing percutaneous coronary intervention Am J Cardiol 103 2009 1339 1343
21. J.L. Mega, S.L. Close, and S.D. Wiviott Cytochrome p-450 polymorphisms and response to clopidogrel N Engl J Med 360 2009 354 362
22. CYP2C19 allele nomenclature http://www.cypalleles.ki.se/cyp2c19.htm Accessed September 30, 2009
23. N. von Beckerath, A. Kastrati, and A. Wieczorek A double-blind, randomized study on platelet aggregation in patients treated with a daily dose of 150 or 75 mg of clopidogrel for 30 days Eur Heart J 28 2007 1814 1819
24. D.J. Angiolillo, E. Bernardo, and J. Palazuelos Functional impact of high clopidogrel maintenance dosing in patients undergoing elective percutaneous coronary interventions Results of a randomized study Thromb Haemost 99 2008 161 168
25. P. Gladding, M. Webster, and I. Zeng The pharmacogenetics and pharmacodynamics of clopidogrel response: an analysis from the PRINC (Plavix Response in Coronary Intervention) trial J Am Coll Cardiol Intv 1 2008 620 627
26. B. Aleil, L. Jacquemin, and F. De Poli Clopidogrel 150 mg/day to overcome low responsiveness in patients undergoing elective percutaneous coronary intervention J Am Coll Cardiol Intv 2008 631 638
27. S. Matetzky, P. Fefer, B. Shenkman, D. Varon, N. Savion, and H. Hod Effectiveness of reloading to overcome clopidogrel nonresponsiveness in patients with acute myocardial infarction Am J Cardiol 102 2008 524 529
28. D.J. Angiolillo, M.A. Costa, and S.B. Shoemaker Functional effects of high clopidogrel maintenance dosing in patients with inadequate platelet inhibition on standard dose treatment Am J Cardiol 101 2008 440 445
29. D.J. Angiolillo, S.B. Shoemaker, and B. Desai Randomized comparison of a high clopidogrel maintenance dose in patients with diabetes mellitus and coronary artery disease: results of the Optimizing Antiplatelet Therapy in Diabetes Mellitus (OPTIMUS) study Circulation 115 2007 708 716
30. N. Bonello-Palot, S. Armero, and F. Paganelli Relation of body mass index to high on-treatment platelet reactivity and of failed clopidogrel dose adjustment according to platelet reactivity monitoring in patients undergoing percutaneous coronary intervention Am J Cardiol 104 2009 1511 1515
31. Plavix package insert http://www.plavix.com Accessed March 30, 2010
32. J. van Giezen, L. Nilsson, and P. Berntsson Ticagrelor binds to human P2Y(12) independently from ADP but antagonizes ADP-induced receptor signaling and platelet aggregation J Thromb Haemost 7 2009 1556 1565
33. M.J. Price, P.B. Berger, and D.J. Angiolillo Evaluation of individualized clopidogrel therapy after drug-eluting stent implantation in patients with high residual platelet reactivity: design and rationale of the GRAVITAS trial Am Heart J 157 2009 818 824 824 e1
34. D.J. Angiolillo, A. Fernandez-Ortiz, and E. Bernardo Platelet aggregation according to body mass index in patients undergoing coronary stenting: should clopidogrel loading-dose be weight adjusted? J Invasive Cardiol 16 2004 169 174
35. L. Ang, V. Palakodeti, and A. Khalid Elevated plasma fibrinogen and diabetes mellitus are associated with lower inhibition of platelet reactivity with clopidogrel J Am Coll Cardiol 52 2008 1052 1059
36. P.A. Gurbel, K.P. Bliden, B.L. Hiatt, and C.M. O'Connor Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity Circulation 107 2003 2908 2913
37. J.T. Brandt, C.D. Payne, and S.D. Wiviott A comparison of prasugrel and clopidogrel loading doses on platelet function: magnitude of platelet inhibition is related to active metabolite formation Am Heart J 153 2007 66.e916
38. P.A. Gurbel, K.P. Bliden, and K. Butler Response to ticagrelor in clopidogrel nonresponders and responders and effect of switching therapies: the RESPOND study Circulation 121 2010 1188 1199